Skip to main content

Advertisement

Figure 3 | Journal of Translational Medicine

Figure 3

From: Optimizing patient derived mesenchymal stem cells as virus carriers for a Phase I clinical trial in ovarian cancer

Figure 3

Dynamic real time monitoring of MSC migration using the xCELLigence chemotaxis assay. (A) The extent of hMSC migration is dose dependent on the concentration of fetal bovine serum (FBS) in the media. FBS concentration ranged from no FBS to 20% FBS in alpha-MEM. (B) Migration of hMSC or ovarian MSC (FB6-8) towards alpha-MEM supplemented with 5% FBS. Migration of ovMSC (C) FB7 or (D) FB8 towards conditioned media harvested from SKOV3ip.1 ovarian cancer cell line or from primary ovarian cancer cells isolated from clinical specimens (AMHAK095, AMEB166). Representative data from duplicate experiments.

Back to article page